# Zepbound vs. Wegovy: Understanding GLP-1 Drugs for Weight Loss
Zepbound and Wegovy represent the same active ingredient, tirzepatide and semaglutide respectively, but serve different purposes in weight management. Both drugs work by mimicking glucagon-like peptide-1 (GLP-1), a hormone that regulates appetite and blood sugar.
Wegovy, made by Novo Nordisk, targets weight loss specifically. Zepbound, manufactured by Eli Lilly, was originally designed for diabetes management but received FDA approval for chronic weight management in 2023. The key distinction lies in their chemical formulation and approved uses rather than dramatically different results.
Wegovy uses semaglutide once weekly via injection. Clinical trials show patients lose roughly 15-22 percent of body weight over 68 weeks. Zepbound uses tirzepatide, also injected weekly, with trials demonstrating 18-22 percent weight loss at the highest dose. Both drugs suppress appetite and slow stomach emptying, helping users feel fuller longer.
Cost and insurance coverage vary significantly. Wegovy typically costs $900-$1,400 monthly without insurance, while Zepbound ranges from $800-$1,200. Insurance coverage depends on individual plans and whether the medication is prescribed for weight loss versus diabetes management.
Side effects occur similarly with both drugs. Nausea, vomiting, diarrhea, and constipation appear most frequently during initial treatment. Some users report these effects diminish as their bodies adjust. Both medications require ongoing use. Stopping either drug typically results in weight regain within months.
For families considering these options, consult a doctor about your specific health situation. Neither drug replaces healthy eating and physical activity. Both require medical supervision and ongoing monitoring. Insurance